Altimmune (ALT) Expected to Release Earnings on Thursday

Altimmune (NASDAQ:ALT) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Altimmune to announce earnings of ($0.14) per share and revenue of $0.00 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:30 AM ET.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02. On average, analysts expect Altimmune to post ($0.58) EPS for the current fiscal year and ($0.54) EPS for the next fiscal year.

Altimmune Trading Up 2.2%

Shares of NASDAQ:ALT traded up $0.04 during midday trading on Tuesday, reaching $2.06. The company’s stock had a trading volume of 234,360 shares, compared to its average volume of 4,216,692. The firm has a market cap of $401.68 million, a price-to-earnings ratio of -2.65 and a beta of 0.06. The company has a quick ratio of 26.78, a current ratio of 26.78 and a debt-to-equity ratio of 0.07. Altimmune has a 1 year low of $1.99 and a 1 year high of $6.44. The business has a 50 day moving average price of $2.80 and a 200 day moving average price of $3.28.

Analyst Ratings Changes

Several research firms recently weighed in on ALT. HC Wainwright reiterated a “buy” rating on shares of Altimmune in a research report on Tuesday, July 28th. Evercore restated an “outperform” rating on shares of Altimmune in a report on Wednesday, September 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research note on Monday, September 21st. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Altimmune has an average rating of “Moderate Buy” and an average target price of $14.33.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for obesity and liver diseases. The company’s research programs are designed to address metabolic and inflammatory conditions with significant unmet medical needs.

Altimmune’s lead product candidate is pemvidutide, an investigational dual GLP-1 and glucagon receptor agonist being evaluated for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease.